Patricia TT, Jiménez-Ríos P, Olvera-Sumano V

Language: Spanish
References: 9
Page: 90-93
PDF size: 371.87 Kb.

ABSTRACT

Introduction: surgery is one of the first-line treatment options for numerous types of cancer; in which the use of opioids for the management of trans and post-operative pain is necessary; However, numerous studies associate a negative effect of these on immunoregulation and cancer recurrence. Material and methods: cohort study, longitudinal, observational, analytical, in patients with malignant ovarian tumor and cytoreductive surgery between 2016 to 2018, in whom tumor recurrence was evaluated at five years in two groups: those patients undergoing multimodal anesthesia and a second group of patients undergoing balanced general anesthesia. Results: 202 files were included, with tumor recurrence observed in 80 (39.6%), of which: 14 (11.2%) were managed with balanced general anesthesia (AGB) and 66 (52.8%) with multimodal anesthesia (MA). The AGB group reported OR = 3.48 (95% CI 1.33-9.06); while in the MA group the OR = 0.29 (95% CI 0.11-0.74) times greater risk of recurrence at five years. Conclusions: the inclusion of multimodal anesthesia blocks or decreases the response to surgical stress, as well as the inflammatory response, reducing the intraoperative use of volatile anesthetics and minimizing the requirement for opioids; which leads to a better immune response and translates into a lower risk of recurrence at five years.

REFERENCES

1. Webb PM, Jordan SJ. Epidemiology of epithelial ovarian cancer. Best Pract Res Clin Obstet Gynaecol. 2017;41:3-14.

2. Sekandarzad MW, van Zundert AAJ, Doornebal CW, Hollmann MW. Regional anesthesia and analgesia in cancer care: is it time to break the bad news? Curr Opin Anaesthesiol. 2017;30:606-612.

3. Boland JW, McWilliams K, Ahmedzai SH, Pockley AG. Effects of opioids on immunologic parameters that are relevant to anti-tumour immune potential in patients with cancer: a systematic literature review. Br J Cancer. 2014;111:866-873.

4. Weng M, Chen W, Hou W, Li L, Ding M, Miao C. The effect of neuraxial anesthesia on cancer recurrence and survival after cancer surgery: an updated meta-analysis. Oncotarget. 2016;7:15262-15273. doi: 10.18632/oncotarget.7683.

5. Zhang D, Jiang J, Liu J, Zhu T, Huang H, Zhou C. Effects of perioperative epidural analgesia on cancer recurrence and survival. Front Oncol. 2022;11:798435.

6. Cakmakkaya OS, Kolodzie K, Apfel CC, Pace NL. Anaesthetic techniques for risk of malignant tumour recurrence. Cochrane Database Syst Rev. 2014;2014:CD008877.

7. Amaram-Davila J, Davis M, Reddy A. Opioids and cancer mortality. Curr Treat Options Oncol. 2020;21:22.

8. Elias KM, Kang S, Liu X, Horowitz NS, Berkowitz RS, Frendl G. Anesthetic selection and disease-free survival following optimal primary cytoreductive surgery for stage III epithelial ovarian cancer. Ann Surg Oncol. 2015;22:1341-1348.

9. Tseng JH, Cowan RA, Afonso AM, Zhou Q, Iasonos A, Ali N, et al. Perioperative epidural use and survival outcomes in patients undergoing primary debulking surgery for advanced ovarian cancer. Gynecol Oncol. 2018;151:287-293. doi: 10.1016/j.ygyno.2018.08.024.